Curis (CRIS) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silexion Therapeutics is the larger company by market cap ($3.1 million vs $1.6 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | SLXN |
|---|---|---|
| Share price | $0.6712 | $0.2146 |
| Market cap | $1.63M | $3.11M |
| 1-day change | -5.38% | -8.64% |
| P/E ratio (TTM) | 0.54 | — |
| EPS (TTM) | $1.25 | $-27.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $39.40 |
| 52-week low | $0.61 | $0.2079 |
| Distance from 52-week high | -98.00% | -99.46% |
| Analyst consensus | none | none |
| Avg. price target upside | +6257.27% | +2229.92% |
| Average volume | 201.33K | 10.05M |
| Shares outstanding | 2.43M | 14.47M |
| Employees | 20 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
CRIS vs SLXN FAQ
Which is bigger, Curis or Silexion Therapeutics?
Silexion Therapeutics (SLXN) is larger, with a market capitalization of $3.11M compared with $1.63M for Curis (CRIS).
Are Curis and Silexion Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.